Biofilm formation on medical devices is associated with hospital-acquired (nosocomial) infections. Due to biofilms’ high tolerance to antibiotics, classical treatments lack efficacy, and removal of the biofilm-contaminated device is often the only therapeutic option. Hence, control of biofilms is a major concern with important health and economical issues. We developed in vitro and in vivo models to evaluate novel anti-biofilm strategies.
PREVENTING BIOFILM FORMATION
Studies of bacterial interactions within mixed communities revealed that bacteria produce non-biocidal anti-adhesion polysaccharides. These high-molecular weight polymers alter surface physico-chemical properties and prevent biofilm formation by a wide range of Gram-positive and Gram-negative bacteria. While these studies shed new light on competitive or cooperative behaviors affecting population dynamics, it suggests that anti-adhesion molecules, or other non-biocidal bio-inspired strategies could constitute a therapeutic alternative to limit biofilm formation on medical devices.
Rendueles, O.; Kaplan, J.B. and J.M. Ghigo. (2012). Antibiofilm polysaccharides Minireview. Environmental Microbiology
Rendueles, O. and J.M. Ghigo. (2012). Multi-species biofilms: How to avoid unfriendly neighbors. FEMS Microbiology Reviews
We developed a clinically relevant in vivo model of catheter-associated biofilm infections to design and test biofilm-eradication approaches applicable to contaminated totally implantable venous access port (TIVAP) catheters. We are currently developing protocols with collaborating clinicians to improve strategies to reduce the incidence of biofilm-associated infections on TIVAPs.
Lebeaux, D., J.M. Ghigo, and C. Beloin. (2014). Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance towards antibiotics Microbiology and Molecular Biology Reviews
Lebeaux, D., N. Fernández-Hidalgo, A. Chauhan, S. Lee, J.M. Ghigo, B. Almirante, and C. Beloin. (2014). Management of infections related to totally implantable venous-access port: challenges and perspectives.The Lancet Infectious Diseases